| Name | Title | Contact Details |
|---|
McBride Orthopedic Hospital opened in 2005 as a full-service orthopedic hospital. McBride has grown to include a board-certified physician staff of 28, practicing at five metro locations and several outreach clinics in rural communities. The physicians continue their close involvement with athletes of all ages, serving as team physicians for many of the local professional, collegiate, and high school athletes.
Acumen Research Group Inc. is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A World Leader in Pediatric Healthcare Founded in 1950 by Variety Clubs International, Nicklaus Children s Hospital, formerly Miami Children s Hospital, operates South Florida’s only licensed specialty hospital exclusively for children, with more than 650 attending physicians and over 130 pediatric sub-specialists. The 289-bed nonprofit hospital is renowned for excellence in all aspects of pediatric medicine and routinely has many programs ranked among the nation’s best by U.S. News and World Report. The organization has grown and evolved into the Miami Children s Health System (MCHS) which includes Miami Children s Health Foundation, the organization s 501c3 fundraising arm; a network of eight nonprofit outpatient centers situated in Miami-Dade, Broward and Palm Beach counties; Pediatric Specialty Group, Inc., a nonprofit physician practice subsidiary; a management services organization, and an ambulatory surgery center (opening soon), as well as an e-commerce line of children s wellness and safety products that support the hospital s mission of serving the region’s pediatric population. MCHS is the region’s only healthcare system exclusively for children.
Blistex Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Oak Brook, IL. To find more information about Blistex Inc., please visit www.blistex.com
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.